National Cancer Center is leading the new drug development in Japan.

再生ボタン

Our Achievement

200patients
Number of Patients per year
enrolled in phase 1 trials
41
Number of ongoing
Phase 1 trials
15
Number of ongoing FIH
phase 1 trials
75%
Rate of global trials in FIH
phase 1 trials

Phase 1 Trials
Professional Team

Our program shares the vision and brings the state-of-the-art to our patients based on research and the patient-centered patient care with the assurance of the safety.

We accelerate early-phase cancer
drug development

National Cancer Center Hospital plays a crucial role in anti-cancer drug development. Recently, the new drug development has been getting more globalized to keep up with the worldwide trend. Participation in the global First-in-Human trials is pressing issues for us. We aim to accelerate new drug development and deliver more precise new anti-cancer drugs for patients

国立がん研究センター 中央病院 先端医療科のスタッフ一同